Is Bio-Techne Corporation Stock Underperforming the S&P 500?
Valued at a market cap of $9.3 billion, Bio-Techne Corporation (TECH) is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. Based in Minneapolis, Minnesota, the company operates through Protein Sciences and Diagnostics & Genomics segments.
Companies worth between $2 billion to $10 billion are generally classified as “mid-cap stocks," and Bio-Techne fits this criterion perfectly. The company aids in drug discovery efforts and provides the means for accurate clinical tests and diagnoses with thousands of products in its portfolio.
Active Investor: FREE newsletter going behind the headlines on the hottest stocks to uncover new trade ideas
Bio-Techne's stock prices have fallen 31.5% from its 52-week high of $85.57 touched on May 15, 2024. In the last three months, shares of Bio-Techne have slipped 19.7%, notably lagging behind the S&P 500 Index’s ($SPX) 6% decrease.
On a YTD basis, shares of TECH have dropped 18.6%, compared to SPX’s 4.6% decline during the same period. In addition, over the last 52 weeks, TECH crumbled 16.7%, underperforming the S&P 500’s 6.8% return.
To confirm the recent downturn, TECH stock has traded consistently below its 50-day and 200-day moving averages since early February.
TECH shares surged over 3.7% after surpassing Wall Street forecasts with its Q2 2025 earnings on Feb. 5, reporting $297 million in revenue and an adjusted EPS of $0.42. Improving biopharma end-market conditions, along with strong demand for cell and gene therapy workflow solutions drove growth of 7% year-over-year in the Protein Sciences Segment to $211.6 million. Meanwhile, solid commercial execution in Diagnostics & Spatial Biology resulted in 12% organic and reported growth for the segment.
Further, in comparison, peer Adaptive Biotechnologies Corporation (ADPT) has outpaced TECH. On a YTD basis, the stock gained 23.9%. Also, shares of ADPT advanced 131.5% over the past 52 weeks.
Despite TECH’s underperformance compared to the broader market over the past year, analysts are bullish about its prospects. The stock has a consensus rating of “Strong Buy” from the 14 analysts covering it. Its mean price target of $83.61 suggests a staggering 42.6% upside potential from current price levels.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
- Should You Buy the Dip in Nvidia Stock in April 2025?
- Is Tesla Stock a Buy, Sell, or Hold Ahead of Saudi Arabia Launch?
- ‘Sell the Rumor, Buy the News’: Why Analysts Think You Should Buy the Dip in Nvidia Stock After Trump’s ‘Liberation Day’
- Tesla Stock Short Sellers Have Made $10 BILLION in 2025. Should You Sell TSLA?
